IS4847A - Aðferð til meðferðar gegn hjartabilun þar sem notuð eru mótlyf gegn endóþelíni - Google Patents

Aðferð til meðferðar gegn hjartabilun þar sem notuð eru mótlyf gegn endóþelíni

Info

Publication number: IS4847A
Authority: IS; Iceland
Prior art keywords: heart failure; treatment; endothelin antagonists; blooded animal; warm blooded
Prior art date: 1996-04-04

Application number

IS4847A

Other languages

English (en)

Inventor

J. Lynch Joseph

-Tang Shen You

Original Assignee

Banyu Pharmaceutical Co. Ltd.

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1996-04-04

Filing date

1998-09-15

Publication date

1998-09-15

1998-09-15 Application filed by Banyu Pharmaceutical Co. Ltd. filed Critical Banyu Pharmaceutical Co. Ltd.

1998-09-15 Publication of IS4847A publication Critical patent/IS4847A/is

Links

206010019280 Heart failures Diseases 0.000 title abstract 2
102000002045 Endothelin Human genes 0.000 title 1
108050009340 Endothelin Proteins 0.000 title 1
239000005557 antagonist Substances 0.000 title 1
ZUBDGKVDJUIMQQ-UBFCDGJISA-N endothelin-1 Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(O)=O)NC(=O)[C@H]1NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@@H](CC=2C=CC(O)=CC=2)NC(=O)[C@H](C(C)C)NC(=O)[C@H]2CSSC[C@@H](C(N[C@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N2)=O)NC(=O)[C@@H](CO)NC(=O)[C@H](N)CSSC1)C1=CNC=N1 ZUBDGKVDJUIMQQ-UBFCDGJISA-N 0.000 title 1
208000009982 Ventricular Dysfunction Diseases 0.000 abstract 1
239000002308 endothelin receptor antagonist Substances 0.000 abstract 1
230000006815 ventricular dysfunction Effects 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Veterinary Medicine (AREA)
Chemical & Material Sciences (AREA)
Public Health (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Epidemiology (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Chemical Kinetics & Catalysis (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Pulmonology (AREA)
Urology & Nephrology (AREA)
Hospice & Palliative Care (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Pyridine Compounds (AREA)
Plural Heterocyclic Compounds (AREA)
Materials For Photolithography (AREA)
Photosensitive Polymer And Photoresist Processing (AREA)

IS4847A 1996-04-04 1998-09-15 Aðferð til meðferðar gegn hjartabilun þar sem notuð eru mótlyf gegn endóþelíni IS4847A (is)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US1488296P	1996-04-04	1996-04-04
PCT/US1997/003737 WO1997037665A1 (en)	1996-04-04	1997-03-19	Method of treating heart failure with endothelin antagonists

Publications (1)

Publication Number	Publication Date
IS4847A true IS4847A (is)	1998-09-15

Family

ID=21768326

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
IS4847A IS4847A (is)	1996-04-04	1998-09-15	Aðferð til meðferðar gegn hjartabilun þar sem notuð eru mótlyf gegn endóþelíni

Country Status (25)

Country	Link
US (3)	US5834483A (is)
EP (1)	EP0906108B1 (is)
JP (2)	JP3345891B2 (is)
KR (1)	KR20000005178A (is)
CN (1)	CN1215335A (is)
AT (1)	ATE297739T1 (is)
AU (1)	AU723351B2 (is)
BG (1)	BG102716A (is)
BR (1)	BR9708525A (is)
CA (1)	CA2249330C (is)
CZ (1)	CZ296098A3 (is)
DE (1)	DE69733557T2 (is)
EA (1)	EA003587B1 (is)
EE (1)	EE9800315A (is)
ES (1)	ES2241047T3 (is)
HU (1)	HUP9903893A3 (is)
IL (1)	IL126175A (is)
IS (1)	IS4847A (is)
NO (1)	NO984564L (is)
NZ (1)	NZ331789A (is)
PL (1)	PL329077A1 (is)
SK (1)	SK130098A3 (is)
TR (1)	TR199801988T2 (is)
UA (1)	UA50761C2 (is)
WO (1)	WO1997037665A1 (is)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO1997037665A1 (en)	1996-04-04	1997-10-16	Banyu Pharmaceutical Co., Ltd.	Method of treating heart failure with endothelin antagonists
AU711936B2 (en) *	1996-08-09	1999-10-28	Banyu Pharmaceutical Co., Ltd.	Stereoselective deoxygenation reaction
EP1049691B1 (en)	1998-01-21	2004-02-18	Banyu Pharmaceutical Co., Ltd.	Substituted 5-(2,2-difluoro-1,3-benzodioxol-5-yl) cyclopentenopyridine derivative
US8168616B1 (en)	2000-11-17	2012-05-01	Novartis Ag	Combination comprising a renin inhibitor and an angiotensin receptor inhibitor for hypertension
JPWO2004060885A1 (ja) *	2002-12-27	2006-05-11	株式会社カネカ	光学活性２−チオメチル−３−フェニルプロピオン酸誘導体およびその合成中間体の製造法
CA2545641A1 (en)	2003-11-17	2005-06-02	Novartis Ag	Use of organic compounds
GB0327839D0 (en)	2003-12-01	2003-12-31	Novartis Ag	Organic compounds
JP2007529459A (ja)	2004-03-17	2007-10-25	ノバルティスアクチエンゲゼルシャフト	治療に置けるレニン阻害剤の使用
JP4967136B2 (ja)	2005-06-24	2012-07-04	国立大学法人東京医科歯科大学	薬剤溶出性ステント
WO2011116115A1 (en)	2010-03-16	2011-09-22	Novartis Ag	Aliskiren composition comprising a medium chain fatty acid, their process of manufacturing

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4971959A (en) *	1987-04-14	1990-11-20	Warner-Lambert Company	Trisubstituted phenyl analogs having activity for congestive heart failure
GB9007762D0 (en) *	1990-04-05	1990-06-06	Beecham Group Plc	Novel compounds
US5565485A (en) *	1993-03-19	1996-10-15	Merck & Co., Inc.	Biphenyl compounds useful or endothelin antagonists
ES2172535T3 (es)	1993-04-27	2002-10-01	Smithkline Beecham Corp	Antagonistas de los receptores de la endotelina.
US5571813A (en) *	1993-06-10	1996-11-05	Beiersdorf-Lilly Gmbh	Fused pyrimidine compounds and their use as pharmaceuticals
US5389620A (en) *	1993-08-18	1995-02-14	Banyu Pharmaceutical Co., Ltd.	Endothelin antagonistic heteroaromatic ring-fused cyclopentene derivatives
AU675870B2 (en) *	1993-08-18	1997-02-20	Msd K.K.	Endothelin antagonistic heteroaromatic ring-fused cyclopentene derivatives
US5658943A (en) *	1995-01-05	1997-08-19	Warner-Lambert Company	Phenylalanine derivatives as endothelin antagonists
WO1997037665A1 (en) *	1996-04-04	1997-10-16	Banyu Pharmaceutical Co., Ltd.	Method of treating heart failure with endothelin antagonists

1997
- 1997-03-19 WO PCT/US1997/003737 patent/WO1997037665A1/en not_active Ceased
- 1997-03-19 JP JP53619497A patent/JP3345891B2/ja not_active Expired - Fee Related
- 1997-03-19 ES ES97914955T patent/ES2241047T3/es not_active Expired - Lifetime
- 1997-03-19 AU AU22025/97A patent/AU723351B2/en not_active Ceased
- 1997-03-19 UA UA98105222A patent/UA50761C2/uk unknown
- 1997-03-19 EA EA199800889A patent/EA003587B1/ru not_active IP Right Cessation
- 1997-03-19 IL IL12617597A patent/IL126175A/xx not_active IP Right Cessation
- 1997-03-19 HU HU9903893A patent/HUP9903893A3/hu unknown
- 1997-03-19 NZ NZ331789A patent/NZ331789A/xx unknown
- 1997-03-19 EP EP97914955A patent/EP0906108B1/en not_active Expired - Lifetime
- 1997-03-19 PL PL97329077A patent/PL329077A1/xx unknown
- 1997-03-19 CA CA002249330A patent/CA2249330C/en not_active Expired - Fee Related
- 1997-03-19 EE EE9800315A patent/EE9800315A/xx unknown
- 1997-03-19 AT AT97914955T patent/ATE297739T1/de not_active IP Right Cessation
- 1997-03-19 CZ CZ982960A patent/CZ296098A3/cs unknown
- 1997-03-19 KR KR1019980707850A patent/KR20000005178A/ko not_active Ceased
- 1997-03-19 TR TR1998/01988T patent/TR199801988T2/xx unknown
- 1997-03-19 DE DE69733557T patent/DE69733557T2/de not_active Expired - Lifetime
- 1997-03-19 BR BR9708525A patent/BR9708525A/pt not_active Application Discontinuation
- 1997-03-19 SK SK1300-98A patent/SK130098A3/sk unknown
- 1997-03-19 CN CN97193645A patent/CN1215335A/zh active Pending
- 1997-03-26 US US08/824,848 patent/US5834483A/en not_active Expired - Fee Related
1998
- 1998-08-11 US US09/132,514 patent/US6087360A/en not_active Expired - Lifetime
- 1998-08-21 BG BG102716A patent/BG102716A/xx unknown
- 1998-09-15 IS IS4847A patent/IS4847A/is unknown
- 1998-09-30 NO NO984564A patent/NO984564L/no not_active Application Discontinuation
2000
- 2000-02-22 US US09/507,666 patent/US6380195B1/en not_active Expired - Fee Related
2001
- 2001-12-07 JP JP2001374870A patent/JP2002220337A/ja active Pending

Also Published As

Publication number	Publication date
HUP9903893A2 (hu)	2001-04-28
EP0906108A4 (en)	2000-12-06
JP2002220337A (ja)	2002-08-09
ATE297739T1 (de)	2005-07-15
DE69733557D1 (de)	2005-07-21
AU723351B2 (en)	2000-08-24
JP2000510824A (ja)	2000-08-22
US6380195B1 (en)	2002-04-30
EE9800315A (et)	1999-06-15
ES2241047T3 (es)	2005-10-16
US6087360A (en)	2000-07-11
AU2202597A (en)	1997-10-29
EP0906108B1 (en)	2005-06-15
CA2249330C (en)	2005-08-09
BG102716A (en)	1999-09-30
DE69733557T2 (de)	2005-11-03
CA2249330A1 (en)	1997-10-16
CN1215335A (zh)	1999-04-28
PL329077A1 (en)	1999-03-15
HUP9903893A3 (en)	2001-05-28
IL126175A (en)	2003-05-29
EA199800889A1 (ru)	1999-04-29
WO1997037665A1 (en)	1997-10-16
UA50761C2 (uk)	2002-11-15
NO984564L (no)	1998-12-04
NZ331789A (en)	2000-05-26
NO984564D0 (no)	1998-09-30
IL126175A0 (en)	1999-05-09
BR9708525A (pt)	1999-08-03
CZ296098A3 (cs)	1999-06-16
EA003587B1 (ru)	2003-06-26
US5834483A (en)	1998-11-10
TR199801988T2 (xx)	2000-08-21
SK130098A3 (en)	1999-05-07
EP0906108A1 (en)	1999-04-07
JP3345891B2 (ja)	2002-11-18
KR20000005178A (ko)	2000-01-25

Publication	Publication Date	Title
CY1110282T1 (el)	2015-01-14	Ενωσεις για την αγωγη της απωλειας βαρους
UA49869C2 (uk)	2002-10-15	Нафтил-заміщені похідні бензимідазолу, фармацевтична композиція, спосіб лікування (варіанти) та спосіб інгібування людського фактора
IL130083A0 (en)	2000-02-29	3-Pyridyl enantiomers and their use as analgesics
CY1109191T1 (el)	2014-07-02	Μια νεα χρηση της δεφεριπρονης
BG106118A (en)	2002-05-31	Method for the treatment of fibrosis using an antagonist of the integrin alpha-4 subunit
ES2166001T3 (es)	2002-04-01	Utilizacion de compuestos antimineralcorticoides contra el sindrome de abstinencia de narcoticos.
IS4847A (is)	1998-09-15	Aðferð til meðferðar gegn hjartabilun þar sem notuð eru mótlyf gegn endóþelíni
PT1039900E (pt)	2004-09-30	Agentes terapeuticos
CA2156481A1 (en)	1994-09-01	5-ht2 receptor antagonist compositions useful in treating venous conditions
MX9701187A (es)	1997-05-31	Nuevas lactamas naftofusionadas n-substituidas.
WO2000048446A3 (en)	2001-02-08	Use of antagonists of pg-e for the treatment of neuropathic pain
EP1090635A3 (en)	2002-02-27	Use of ferulic acid for treating hypertension
ATE242641T1 (de)	2003-06-15	Behandlung von stressinduzierten hautkrankheiten unter verwendung von corticoliberin (crh)- antagonisten und inhibitoren der hautmastzell- degranulation
MY126321A (en)	2006-09-29	Use of (alpha)-adrenoreceptor antagonists in the prevention and treatment of cancer.
WO1999065475A3 (en)	2000-04-06	Combination of phentolamine and apomorphine for the treatment of human sexual function and dysfunction
ATE149840T1 (de)	1997-03-15	Behandlung von leberkrebs
ATE268170T1 (de)	2004-06-15	Verwendung von bernsteisäure oder deren salze zur behandlung von insulinresistenz
DK0572549T3 (da)	2003-01-06	Behandling af ikke-småcellet lungecarcinom
DE69734349D1 (de)	2006-02-23	Behandlung von knochenleiden mit adrenomedullin